Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis

APLAR Journal of Rheumatology

Volumn 10, Issue 4, 2007, Pages 295-299

  Nagasawa, Hayato ^a   Kameda, Hideto ^a   Amano, Koichi ^a   Takeuchi, Tsutomu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

CRP; Lansbury Articular Index; Swollen joint count

Indexed keywords

ACTARIT; AUROTHIOMALATE; BUCILLAMINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; STROMELYSIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

EID: 36749051813     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2007.00309.x     Document Type: Article

References (26)

1. Firestein GS (2001) Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley's Textbook of Rheumatology, 6th edn, pp. 921-66. W.B. Saunders, Philadelphia.
2. Okada Y (2000) Matrix-degrading metalloproteinases and their roles in joint destruction. Mod Rheumatol 10, 121-8.
3. Okada Y (2001) Proteinases and matrix degradation. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley's Textbook of Rheumatology, 6th edn, pp. 55-72. W.B. Saunders, Philadelphia.
4. Lansbury J (1966) Method for evaluating rheumatoid arthritis. In: Hollander JL (ed.) Arthritis and Allied Conditions, pp. 269-91. Lea & Febiger, Philadelphia.
5. Nagasawa H, Kameda H, Amano K, Takeuchi T (2005) Clinical significance of serum matrix metalloproteinase-3 level in patients with rheumatoid arthritis. Inflamm Regen 25, 60-4 (in Japanese).
6. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
7. Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140, 659-62.
8. Obata K, Iwata K, Okada Y, et al. (1992) A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin Chim Acta 211, 59-72.
9. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 39, 34-40.
10. Sekiguchi N, Kameda H, Amano K, Takeuchi T (2006) Efficacy and safety of bucillamine, a d -penicillamine analogue, in patients with rheumatoid arthritis. Mod Rheumatol 16, 85-91.
11. Yokouchi K, Mitsusima T, Hara H, Tamei H (2000) Evaluation of PANACLEAR MMP-3 PLATE kit on an automatic microplate processor and establishment of reference intervals. J New Rem Clin 50, 215-21 (in Japanese).
12. Ballou SP, Kushner I (2001) Laboratory evaluation of inflammation. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley's Textbook of Rheumatology, 6th edn, pp. 697-703. W.B. Saunders, Philadelphia.
13. Volanakis JE (2001) Acute-phase proteins in rheumatic disease. In: Koopman WJ (ed.) Arthritis and Allied Conditions, 14th edn, pp. 504-14. Lippincott Williams & Wilkins, Philadelphia.
14. Matteson EL (2001) Rheumatoid arthritis. In: Klippel JH (ed.) Primer on the Rheumatic Disease, 12th edn, pp. 242-69. Arthritis foundation, Atlanta.
15. Firestein GS (2005) Etiology and pathogenesis of rheumatoid arthritis. In: Harris ED, Budd RC, Genovese MC, Firestein GS, Sargent GS, Sledge CB (eds) Kelley's Textbook of Rheumatology, 7th edn, pp. 996-1042. Elsevier Saunders, Philadelphia.
16. Felson DT, Anderson JJ, Boers M, et al. (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36, 729-40.
17. Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M (1998) Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol 16, 533-40.
18. Keyszer G, Lambiri I, Nagel R, et al. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinase 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26, 251-8.
19. Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13, 228-33.
20. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinase-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38, 969-75.
21. Ribbens C, Andre B, Jaspar J-M, et al. (2000) Matrix metalloproteinases-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27, 888-93.
22. Green MJ, Gough AKS, Devlin J, et al. (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42, 83-8.
23. Tchetverikov I, Lard LR, DeGroot J, et al. (2003) Matrix metalloproteinases-3-8-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 62, 1094-9.
24. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2000) Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 27, 2761-8.
25. Roux-Lombard P, Eberhardt K, Saxne T, Dayer JM, Wollheim FA (2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein. relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 40, 544-51.
26. Yamanaka H, Matsuda Y, Tanaka M, et al. (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43, 852-8.